CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.
Trial Details
- NCT ID
- NCT05054257
- Phase
- PHASE1
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
- Status
- RECRUITING
- Cancer Type
- Burkitt Lymphoma Lymphoma
- Interventions
- Autologous CAR19 T lymphocytes
- Locations (sample)
- Prague, Czechia|50.08804,14.42076
Key Eligibility Criteria
- Patient with refractory or relapsing CD19 positive B-ALL or B-NHL defined as:
- B-ALL refractory to treatment or in the second or subsequent relapse (hematological OR molecular), OR
- B-NHL refractory to treatment or in first relapse ineligible for autologous stem cell transplantation (ASCT) or in second to fourth relapse, OR
- B-ALL or B-NHL relapsing after autologous or allogeneic hematopoietic cell transplantation (HCT).
For full eligibility, visit ClinicalTrials.gov.